ANI Pharma (ANIP) Misses Q2 EPS by 6c

ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $0.13, $0.06 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $73.9 million versus the consensus estimate of $71.13 million.

GUIDANCE:

ANI Pharma sees FY2022 EPS of $1.34-$1.62, versus the consensus of $1.43. ANI Pharma sees FY2022 revenue of $295-315 million, versus the consensus of $305 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook
• McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance